[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer].
In the present study we have evaluated the response rate (clinical and histological) to neoadjuvant chemotherapy (NAC), which consist of 3 courses of Bleomycin, Cisplatina, Ifosfamid every 21 days. Twelve patients in stage IIIB cervical cancer were submitted to NAC and 12 (control group)--received standart pelvic radiation to whole pelvis--52 Gy. Depending on the response to NAC 5/12 patients were operated on and the other 7 were irradiated. We have analyzed disease free survival (DFS) of different subgroups, according to second-line treatment and histopathological findings (lymph node metastases) of the operated patients. The results were compared to these of other authors in order to determine the role and place of NAC in the treatment of IIIB cervical cancer patients.
Gorchev
G
G
Kornovski
Ia
Ia
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007069:Ifosfamide / Q000008:administration & dosage; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery
D001761:Bleomycin; D002945:Cisplatin; D007069:Ifosfamide